IVI appoints Actor Lee Bum-Soo as Goodwill Ambassador
‘Guardian of health for children in developing countries’
IVI appointed actor Lee Bum-soo as Goodwill Ambassador of IVI on June 25 at a ceremony held at IVI headquarters on Seoul National University. In attendance at the event were IVI CFO and acting Director General John Morahan, and Prof. Cho Wan-kyoo, Executive Advisor to the Korea Support Committee for IVI, and IVI staff.
Mr. John Morahan said, “We express sincere gratitude to Mr. Lee Bum-soo, who gladly agreed to serve as IVI Goodwill Ambassador,” adding, “Mr. Lee is expected to advocate for the importance of vaccines, and the Korean public’s attention and support of IVI’s endeavors to improve the health of people in developing countries, especially children.
IVI said “Mr. Lee Bum-soo will contribute to communicating and spreading IVI’s work in vaccine development and introduction, which often sounds difficult and complicated for ordinary people to understand, to the general public with friendly and caring images as a father of young girl.”
Mr. Lee said, “It is my great honor to have the opportunity to support IVI, which is striving to improve the health of children who are left behind the benefits of public health,” adding, “I will do my best to ensure that more (Korean) people can sympathize with and extend support to IVI’s noble mission.”
Mr. Lee, who visited IVI headquarters accompanied by his wife Ms. Lee Yoon-jin on the day for the first time, was debriefed on IVI’s research activities, and vaccine introduction projects in countries of Asia and Africa, before taking a guided tour to IVI laboratories after the ceremony.
IVI is conducting activities in the entire vaccine continuum ranging from discovery and development of vaccines, to clinical trials in developing country settings, and sustainable introduction and vaccines in countries in need. Currently, the Institute is working on cholera, typhoid fever and dengue fever as priority diseases in cooperation with the science community, international organizations, governments and industry.
Major achievements include the development of the world’s first low-cost oral cholera vaccine, which was prequalified by the World Health Organization in 2011. The vaccine is more affordable than conventional cholera vaccines, and has been confirmed repeatedly to confer long-term protection against the deadly diarrheal disease. The vaccine has been used to immunize more 1 million people worldwide.